SCL Science Inc. (KOSDAQ:246960)

Market Cap	74.67B +31.4%
Revenue (ttm)	22.01B +364.6%
Net Income	-3.93B
EPS	-120.00
Shares Out	34.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,909
Average Volume	126,263
Open	2,250.00
Previous Close	2,155.00
Day's Range	2,190.00 - 2,265.00
52-Week Range	1,770.00 - 5,110.00
Beta	0.55
RSI	51.88
Earnings Date	Apr 3, 2026

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 246960

Financial Performance

In 2025, SCL Science's revenue was 22.01 billion, an increase of 364.64% compared to the previous year's 4.74 billion. Losses were -3.93 billion, 5.47% more than in 2024.